Search Result

Results for "

wild-type HIV-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV (76) HIV Integrase (1) HIV Protease (23) Antibiotic (1) Autophagy (7) DNA/RNA Synthesis (2) Endogenous Metabolite (5) Fungal (1) HBV (2) Isotope-Labeled Compounds (8) MMP (2) Nucleoside Antimetabolite/Analog (2) Parasite (4) Potassium Channel (1) Reference Standards (10) Reverse Transcriptase (30) SARS-CoV (7) Src (1)
By Research Areas:	Cancer (10) Infection (79) Inflammation/Immunology (7) Neurological Disease (1)
Click Chemistry:	Azide (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: HIV Integrase HIV HIV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10572

Efavirenz 15+ Cited Publications DMP 266; EFV; L-743726	Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite	Infection Cancer
Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-10574

Rilpivirine 5+ Cited Publications R278474; TMC278; DB08864	HIV Reverse Transcriptase	Infection
Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type *HIV* (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .

HY-14588

Lopinavir Maximum Cited Publications 20 Publications Verification ABT-378	HIV HIV Protease SARS-CoV	Infection Neurological Disease Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-17040

Darunavir 15+ Cited Publications TMC114; UIC-94017	HIV HIV Protease	Infection Inflammation/Immunology
Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC₅₀ = 0.003 μM; IC₉₀ = 0.009 μM) with minimal cytotoxicity .

HY-16767

Doravirine 10+ Cited Publications MK-1439	HIV Reverse Transcriptase	Infection Inflammation/Immunology
Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively .

HY-17041

Darunavir Ethanolate 15+ Cited Publications TMC114 Ethanolate	HIV HIV Protease	Infection
Darunavir ethanolate (TMC114 Ethanolate) is a potent *HIV* protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a K_i of 1 nM for wild type HIV-1 protease.

HY-107123

TMC310911 1 Publications Verification ASC-09	HIV Protease	Infection
TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC₅₀ values ranged from 2.2 nM to 14.2 nM for **wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1** isolates. TMC310911 has strong antiviral activity .

HY-16767S1

Doravirine-13C,d3 MK-1439-¹³C,d₃	Isotope-Labeled Compounds HIV Reverse Transcriptase	Infection
Doravirine-13C,d3 (MK-1439-13C,d3) is the deuterium labeled Doravirine (HY-16767). Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively .

HY-10574A

Rilpivirine hydrochloride 5+ Cited Publications TMC-278 hydrochloride	SARS-CoV MMP	Infection
Rilpivirine (R278474) hydrochloride is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine hydrochloride has high antiviral activity against wild-type *HIV* (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine hydrochloride has a high genetic barrier to resistance development of HIV .

HY-19400

DPC-681 DPH-153893	HIV Protease HIV	Infection
DPC-681 is a potent and selective inhibitor of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM.

HY-125028

Hck-IN-1 1 Publications Verification	Src HIV	Infection
Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective Nef-dependent Hck inhibitor with IC₅₀s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively. Hck-IN-1 is a direct and wide HIV-1 Nef antagonists with an IC₅₀ of 100-300 nM for wild-type HIV-1 replication. Hck-IN-1 binds pocket residue Asn126 and has anti-retroviral activity .

HY-134851

HIV-1 inhibitor-6 1 Publications Verification	HIV	Infection
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM .

HY-109014

Tenofovir exalidex CMX-157	HIV HBV Nucleoside Antimetabolite/Analog	Infection
Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant *HIV* strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC₅₀s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV .

HY-15352

BMS 561390 DPC 083	Reverse Transcriptase HIV	Infection
BMS 561390 (DPC 083) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains .

HY-175351

HIV-1-IN-83	HIV Reverse Transcriptase	Infection
HIV-1-IN-83 (Compound 18E) is a *HIV-1* non-nucleoside reverse transcriptase inhibitor with an IC₅₀ of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .

HY-147650

HIV-1 protease-IN-5	HIV Protease	Infection
HIV-1 protease-IN-5 (Compound 13c) is a HIV-1 protease inhibitor with an IC₅₀ of 1.64 nM. HIV-1 protease-IN-5 shows remarkable activity against wild-type and DRV-resistant HIV-1 variants .

HY-162461

HIV-1 inhibitor-66	Reverse Transcriptase HIV	Infection
HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC₅₀ of 40 nM .

HY-105249

RDEA 806	HIV Reverse Transcriptase	Infection
RDEA 806 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent in vitro inhibitory activity against both wild-type *HIV-1* (EC₅₀ = 3.05 nM) and NNRTI-resistant *HIV-1* .

HY-10572B

(Rac)-Efavirenz (Rac)-DMP 266; (Rac)-EFV; (Rac)-L-743726	Autophagy Parasite HIV Endogenous Metabolite Reverse Transcriptase	Infection Cancer
(Rac)-Efavirenz is the isomer of Efavirenz (HY-10572). Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-10572S1

Efavirenz-13C6 DMP 266-¹³C₆; EFV-¹³C₆; L-743726-¹³C₆	Isotope-Labeled Compounds Reverse Transcriptase HIV Autophagy Endogenous Metabolite	Infection Cancer
Efavirenz- ¹³C₆ is the ¹³C-labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-14361

MK-4965	HIV Reverse Transcriptase	Infection
MK-4965 is a nonnucleoside reverse transcriptase inhibitor (NNRTI). MK-4965 displays excellent activities against not only *HIV-1* wild-type (WT) virus but also against a broad panel of NNRTI-resistant viruses and can be used for the research of HIV-1 infection .

HY-10572R

Efavirenz (Standard) DMP 266 (Standard); EFV (Standard); L-743726 (Standard)	Reference Standards Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite	Infection Cancer
Efavirenz (Standard) is the analytical standard of Efavirenz. This product is intended for research and analytical applications. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-163110

NNRT-IN-2	HIV Reverse Transcriptase	Infection
NNRT-IN-2 (compound 7w) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type *HIV-1* and mutant strains. NNRT-IN-2 inhibits HIV-1 reverse transcriptase with an EC₅₀ of 22 nM. NNRT-IN-2 is insensitive to CYP and hERG and has good safety and pharmacokinetic characteristics .

HY-157469

TNT-i NPD3064	HIV	Infection
TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection .

HY-171835

DPC 684	HIV HIV Protease	Infection
DPC 684 is a potent and selective HIV-1 protease inhibitor (IC₉₀ = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC₉₀ = 1.9-6.3 nM). DPC 684 has research significance for HIV .

HY-N16422

Mer-NF5003E	HIV HIV Protease	Infection
Mer-NF5003E is a non-nucleoside reverse transcriptase inhibitor targeting HIV-1 reverse transcriptase (RT) (EC₅₀=50 μM). Mer-NF5003E exhibits inhibitory activity against wild-type HIV-1 and multiple NNRTI-resistant strains (e.g., K103N, Y181C). Mer-NF5003E is promising for research of HIV infections .

HY-10572S

Efavirenz-d5	Reverse Transcriptase HIV Autophagy	Infection Cancer
Efavirenz-d₅ (DMP 266-d₅) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . Efavirenz-d₅ is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14588S1

Lopinavir-d8	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV	Infection
Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-178341

NNRT-IN-13	Reverse Transcriptase HIV	Infection
NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type *HIV-1* (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research .

HY-150549

HIV-1 protease-IN-6	HIV Protease HIV	Infection Inflammation/Immunology
HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC₅₀ of 21 pM and a K_i of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus .

HY-19869

VRX-480773	HIV Reverse Transcriptase	Infection
VRX-480773 is an efficient non-nucleoside reverse transcriptase inhibitor (NNRTI), used for *HIV* infection. VRX-480773 has high specificity for *HIV-1, with an EC₅₀* for wild-type HIV-1 being 0.14 nM. VRX-480773 does not inhibit HIV-2, HBV or HCV, and has no effect on human DNA polymerase α/β. VRX-480773 retains inhibitory activity against Efavirenz (HY-10572) resistant strains, with EC₅₀s mostly < 1 nM. VRX-480773 can be used for research on AIDS .

HY-17040R

Darunavir (Standard) TMC114 (Standard); UIC-94017 (Standard)	HIV HIV Protease Reference Standards	Infection Inflammation/Immunology
Darunavir (Standard) is the analytical standard of Darunavir. This product is intended for research and analytical applications. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .

HY-149936

HIV-1 protease-IN-8	HIV Protease	Infection
HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC₅₀ value of 0.32 nM. HIV-1 protease-IN-8 displays IC₅₀s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1_NL4-3) and drug-resistant variant (HIV-1_MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant .

HY-174303

NNRT-IN-9	HIV Reverse Transcriptase	Infection
NNRT-IN-9 (Compound EG28) is a non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-9 has potent antiviral and anti-resistance activity against wild-type (WT) HIV-1 and various clinically relevant mutations (E138K and K103N + Y181C) with EC₅₀s of 55, 67 and 3910 nM, respectively. NNRT-IN-9 can be used for acquired immune deficiency syndrome (AIDS) research .

HY-10574S

Rilpivirine-d6	Isotope-Labeled Compounds HIV Reverse Transcriptase	Infection
Rilpivirine-d₆ is the deuterium labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .

HY-150769

ZLM-66	HIV	Inflammation/Immunology
ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC₅₀ of 41 nM for wild-type (WT) *HIV-1* reverse transcriptase and an EC₅₀ value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS .

HY-139631

HIV-1 inhibitor-9	HIV	Infection
HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) *HIV-1* strain or multiple NNRTI-resistant strains at low nanomolar levels.

HY-111079

HIV-1 inhibitor-70	HIV Reverse Transcriptase	Others
HIV-1 inhibitor-70 (compound 20) is a bifunctional inhibitor that inhibits both wild-type (WT) and K103N mutant reverse transcriptases (RTs) of HIV-1.

HY-150697

HIV-1 inhibitor-44	HIV	Others
HIV-1 inhibitor-44 (compound 11l) is a HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-44 shows inhibitory activity against wild-type HIV-1 strain with an EC₅₀ value of 0.209 μM .

HY-159984

HIV-1 inhibitor-78	HIV	Infection
HIV-1 inhibitor-78 (compound 15f) is a potent and broad-spectrum non-nucleoside reverse transcriptase inhibitor, with an EC₅₀ of 3 nM for **wild-type HIV-1*. HIV-1* inhibitor-78 can be used for the research of HIV infection .

HY-151938

Reverse transcriptase-IN-3	HIV	Infection
Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of *HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1* wild-type and mutant strains .

HY-149991

HIV-1 inhibitor-56	HIV	Infection
HIV-1 inhibitor-56 (compound 12126065) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-56 has antiviral activity against wild-type HIV-1 in TZM cells with an EC₅₀ value of 0.24 nM. HIV-1 inhibitor-56 penetrates the blood-brain barrier .

HY-155114

HIV-1 inhibitor-59	HIV	Infection
HIV-1 inhibitor-59 (Compound I-5b) is a *HIV-1* inhibitor, with EC₅₀s of 5.62-171 nM against the wild-type (WT) and mutant HIV-1 strains. HIV-1 inhibitor-59 has moderate RT enzyme inhibitory activity (IC₅₀: 0.094-12.0 μM) .

HY-149350

HIV-1 inhibitor-57	HIV	Infection
HIV-1 inhibitor-57 (Compound 12g) is a *HIV* inhibitor. HIV-1 inhibitor-57 is active against wild-type and five prevalent NNRTI-resistant HIV-1 strains with EC₅₀ values ranging from 0.024 to 0.0010 μM. HIV-1 inhibitor-57 forms additional interactions with residues around the binding site in HIV-1 RT .

HY-167135

DPC-082	HIV Reverse Transcriptase	Infection
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of *HIV-1. DPC-082 inhibits wild-type* RF virus with an IC₉₀ of 2.0 nM. DPC-082 inhibits various single and many multiple amino acid substituted HIV-1 mutant viruses .

HY-19925

AIC-292	HIV	Infection
AIC-292 is a potent and selective inhibitor of HIV-1 nonnucleoside reverse transcriptase. AIC-292 inhibits wild-type HIV-1 laboratory strains at low nanomolar concentrations. AIC-292 displays potent antiviral in vivo efficacy in a mouse xenograft model. AIC-292 has the potential for the research of HIV-1 infection .

HY-162253

HIV-1 inhibitor-64	HIV	Infection
HIV-1 inhibitor-64 (Compound 7c) is a wild-type *HIV-1* inhibitor that effectively suppresses the activity of *HIV-1* mutants E138K/Q148K and G140S/Q148R with EC₅₀ values of 62.5 nM and 11.3 nM, respectively. HIV-1 inhibitor-64 exhibits antiviral activity and can be used in the research of AIDS .

HY-10572BR

(Rac)-Efavirenz (Standard) (Rac)-DMP 266 (Standard); (Rac)-EFV (Standard); (Rac)-L-743726 (Standard)	Reference Standards Autophagy Parasite HIV Endogenous Metabolite Reverse Transcriptase	Infection Cancer
(Rac)-Efavirenz (Standard) is the analytical standard of (Rac)-Efavirenz. This product is intended for research and analytical applications. (Rac)-Efavirenz is the isomer of Efavirenz (HY-10572). Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-10572BS

(Rac)-Efavirenz-d4	Isotope-Labeled Compounds Reverse Transcriptase HIV Autophagy	Infection Cancer
(Rac)-Efavirenz-d₄ is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . (Rac)-Efavirenz-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149928

NNRT-IN-1	HIV	Infection
NNRT-IN-1 (compound 8r) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor featuring significantly anti-resistance efficacy. NNRT-IN-1 inhibits the **wild-type HIV-1 and five mutant strains with EC₅₀**s in the nanomolar range. NNRT-IN-1 displays favorable pharmacokinetic properties .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10572

Efavirenz 15+ Cited Publications DMP 266; EFV; L-743726	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite
Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-10572R

Efavirenz (Standard) DMP 266 (Standard); EFV (Standard); L-743726 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite
Efavirenz (Standard) is the analytical standard of Efavirenz. This product is intended for research and analytical applications. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-N16422

Mer-NF5003E	Microorganisms Terpenoids Sesquiterpenes Source Classification	HIV HIV Protease
Mer-NF5003E is a non-nucleoside reverse transcriptase inhibitor targeting HIV-1 reverse transcriptase (RT) (EC₅₀=50 μM). Mer-NF5003E exhibits inhibitory activity against wild-type HIV-1 and multiple NNRTI-resistant strains (e.g., K103N, Y181C). Mer-NF5003E is promising for research of HIV infections .

HY-146364

CI-39	Structural Classification Alkaloids Cruciferae Isatis tinctoria L. Plants Indole Alkaloids Source Classification	DNA/RNA Synthesis HIV
CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibit) antiviral agent with an EC₅₀ of 3.40 μM and an CC₅₀ of >30 μM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activitiessup .

Cat. No.	Product Name	Chemical Structure

HY-16767S1

Doravirine-13C,d3
Doravirine-13C,d3 (MK-1439-13C,d3) is the deuterium labeled Doravirine (HY-16767). Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively .

HY-10572S1

Efavirenz-13C6
Efavirenz- ¹³C₆ is the ¹³C-labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

HY-10572S

Efavirenz-d5

Efavirenz-d₅ (DMP 266-d₅) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . Efavirenz-d₅ is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14588S1

Lopinavir-d8

Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-10574S

Rilpivirine-d6
Rilpivirine-d₆ is the deuterium labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .

HY-10572BS

(Rac)-Efavirenz-d4

(Rac)-Efavirenz-d₄ is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . (Rac)-Efavirenz-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14588S2

Lopinavir-d7

Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-10574S1

Rilpivirine-13C6

Rilpivirine- ¹³C₆ (R278474- ¹³C₆) is ¹³C labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .

Cat. No.	Product Name		Classification

HY-152233

Reverse transcriptase-IN-4		Azide
Reverse transcriptase-IN-4 (compound F10) is a potent and selective non-nucleoside reverse transcriptase (NNRT) inhibitor with an EC₅₀ value of 0.053 μM for wild-type HIV-1 and an EC₅₀ value of 0.26 μM for HIV-1 mutant E138K . Reverse transcriptase-IN-4 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-109014

Tenofovir exalidex CMX-157		Phospholipids
Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant *HIV* strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC₅₀s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks